Although CAR T-cell therapy has been highly effective in hematological cancers, its activity in solid tumors is still constrained by inhibitory checkpoints such as PD-1, LAG-3 and TIM-3, together with the lack of locally available cytokines such as IL-2 needed to sustain T-cell function. Anwita Biosciences Inc. and collaborators aimed to overcome these challenges by developing a strategy integrating an immune checkpoint inhibitor (ICI) with a T-cell stimulatory cytokine.
Researchers from Synklino A/S have published preclinical data supporting the potential of SYN-002, a targeted antiviral therapy that eliminates human cytomegalovirus (HCMV)‑infected cells by specifically targeting US28, a CMV‑encoded receptor expressed during infection.
IL-10-based approaches have shown promise in cancer immunotherapy by activating exhausted CD8+ T cells, but severe hematological toxicities have limited their clinical use. Recent strategies aim to harness IL-10’s antitumor effects while reducing these toxicities.
Celltrion Inc. scored a hat-trick of deals to license new antibody candidates, including a $744 million deal with Kaigene Inc. Nov. 3, and a near $500 million deal with Mustbio Co. Ltd. Oct. 31.
Celltrion Inc. scored a hat-trick of deals to license new antibody candidates, including a $744 million deal with Kaigene Inc. Nov. 3, and a near $500 million deal with Mustbio Co. Ltd. Oct. 31.
Atyr Pharma Inc. has advanced ATYR-0101 into IND-enabling studies for pulmonary fibrosis, and is targeting an IND application in the second half of next year.
Immunostimulant therapy using agonistic cytokines or activating antibodies has been associated with off-target side effects, failure to preferentially activate cytotoxic lymphocytes (CTLs) over regulatory T cells (Treg), and the development of T-cell exhaustion. With the aim of overcoming these issues, researchers from Recourse Biologics Inc. designed a potentially first-in-class immunostimulatory fusion protein.
The tumor microenvironment plays a crucial role in the resistance of solid tumors to immunotherapy. In particular, fibroblast activation protein (FAP)-expressing cancer-associated fibroblasts have been shown to contribute to immune evasion.
Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to selectively deliver IL-21 to PD-1-expressing cells for the treatment of cancer.
Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
